[1] Yangcong, Mafengfeng, Zhongwei, et al. A Study on Professor Yang Peijun’ s Clinical Experience of Modified Treatment of the Restenosis after Stent Implantation for CHD by Gualou Xiebai and Banxia Decoction plus Danshen Yin [J]. Modern Traditional Chinese Medicine, 2020, (05): 25-28. [doi: 10.13424/j.cnki.mtcm.2020.05.007]
A Study on Professor Yang Peijun’ s Clinical Experience of Modified Treatment of the Restenosis after Stent Implantation for CHD by Gualou Xiebai and Banxia Decoction plus Danshen Yin
- Article number:
- 1672-0571(2020)05-0025-04
- Keywords:
- the Restenosis after Stent Implantation for CHD; TCM treatment; Yang Peijun; Gualou Xiebai and Banxia Decoction; Danshen Decoction; clinical experience
- ZTFLH:
- R541.4
- Code:
- A
- Abstract:
- Professor Yang Peijun, as a TCM practitioner of national renown, holds that the pathological factors of the restenosis after stent implantation for CHD( Coronary Heart Disease) are phlegm and stasis and they intertwine with each other to cause the in - stent restenosis. Therefore, the treatment should aim to dispel and clear the phlegm, additionally dispersing lung, calming shen and calming heart as well as harmonizing the form and shen. The clinical effect of modified treatment by using Gualou Xiebai and Banxia( pinellia ternate) Decoction plus Danshen ( salviae miltiorrhizae) Decoction are significant since Professor Yang regulate the blood vessel and xin - shen simultaneously based on the holism of TCM. So the rational application of Western and Chinese therapy can improve patients’ clinical symptoms and their life quality.
References:
[1]林悦涛.冠心病介入治疗后再发胸痹患者的中医证候特点研究[D].广州:广州中医药大学,2011.
[2]胡元会,吴林,周次清.经皮冠状动脉介入治疗后再狭窄的中医病机治法钩玄[J].中国中医基础医学杂志,2003,9(2):14-16.
[3]刘征,于卫国,张蕾,等.经皮冠状动脉介入治疗术后支架内再狭窄的多因素Logistic回归分析[J].中国循证心血管医学杂志,2016,8(3):317-319.
[4]尹琳琳,刘如秀.中医体质学说与冠心病的相关性[J].河南中医,2015,35(8):1785-1787.
[5]谢宇晴,杨力强.冠心病支架植入后再狭窄的中医药治疗研究进展[J].广西中医药大学学报,2013,16(1):74-76.
[6]郭维琴.中医药防治PTCA后RS的研究[J].中医药学刊,2005,33(9):1549-1550.
[7]郭小乐,谢秋利,宋亚茹,等.李庆海教授治疗冠脉支架术后再狭窄的临证经验[J].光明中医,2016,31(4):489-491.
[8]劳闻文,张婕.论中医药治疗冠心病支架植入术后再狭窄的研究进展[J].湖南中医药大学,2018,10(20):141-143.
[9]周宏伟,孟建宏,张红鸽,等.瓜蒌薤白半夏汤治疗冠状动脉粥样硬化性心脏病心绞痛疗效观察[J].中医学报,2018,33(10):2012-2015.
[10]孔令雷,杜冠华.丹参饮的现代研究进展[J].中药药理与床,2019,35(3):197-200.
[11]雷燕,但汉雄,韩林涛,等.“瓜蒌-薤白”药对对大鼠抗急性心肌缺血的药效学研究[J].湖北中医杂志,2013,35(1):68-71.
[12]袁茵,邓思瑶,黄雅晨,等.补阳还五汤?少腹逐瘀汤?丹参饮对寒凝血瘀模型大鼠血小板形态与黏附的影响.吉林中医药,2019,39(1)∶78-81.
[13]郑洪新,李敬林.周学海医学全书[M].北京:中国中医药出版社,2006:569.
[14]王咪咪,李林.唐宗海医学全书[M].北京:中国中医药出版社,2002:86.
[15]陈小兰,郑道国,徐群威,等.南葶苈子提取液对心肌缺血/再灌注大鼠心肌自噬及MAPK/ERK1/2通路的影响[J].中国中医急症,2019,28(8):1349-1353.
[16]王超,王昀,赵海滨.从中医“双心学说”探析冠心病合并焦虑的论治思路[J].环球中医药,2016,9(12):1476-1478.
[17]覃世阳.从“治气”立法治疗冠心病PCI术后伴焦虑障碍的临床研究[D].南宁:广西中医药大学,2018.
[18]王婷婷.针刺结合运动疗法对冠心病PCI术后患者生存质量的影响[D].武汉:湖北中医药大学,2016.
[19]陆强.从中医“治未病”谈中医药在冠心病预防中的重要作用[D].北京:北京中医药大学,2009.
Memo
基金项目:陕西省重大病种中医药创新计划;陕西省中医管理局科研专项(15-SCJH015;15-LC016;LCPT089;15-SCJH016) 通讯作者:齐婧,主治医师?E-mail:qijing0213@163.com